- $39.98m
- $28.65m
- $101.49m
- 71
- 82
- 54
- 79
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.23 | ||
| Price to Tang. Book | 1.86 | ||
| Price to Free Cashflow | 12.53 | ||
| Price to Sales | 0.39 | ||
| EV to EBITDA | 8.51 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.35% | ||
| Return on Equity | -1.78% | ||
| Operating Margin | 0.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 62.2 | 61.93 | 72.81 | 83.61 | 101.49 | 67.42 | 74.45 | 10.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
Directors
- John McLaughlin NEC (69)
- Russell Ellison PRE (73)
- Russell Skibsted CFO (61)
- Paul McGarry CAO (53)
- Michael DeYoung VOP
- Marc Hoffman OTH (60)
- Raymond Pratt OTH (70)
- John Cooper IND (62)
- Allen Nissenson IND (74)
- Robert Radie IND (57)
- Mark Ravich IND (68)
- Andrea Smiley IND (53)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 30th, 2019
- Public Since
- January 27th, 1998
- No. of Shareholders
- 45
- No. of Employees
- 244
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 34,174,687
- Address
- 30142 WIXOM ROAD, WIXOM, 48393
- Web
- https://www.rockwellmed.com/
- Phone
- +1 2489609009
- Contact
- Heather Hunter
- Auditors
- EisnerAmper LLP
Upcoming Events for RMTI
Q1 2025 Rockwell Medical Inc Earnings Call
Rockwell Medical Inc Annual Shareholders Meeting
Rockwell Medical Inc Annual Shareholders Meeting
Q2 2025 Rockwell Medical Inc Earnings Release
Similar to RMTI
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Rockwell Medical share price?
As of Today at 22:57 UTC, shares in Rockwell Medical are trading at $1.17. This share price information is delayed by 15 minutes.
How has the Rockwell Medical share price performed this year?
Shares in Rockwell Medical last closed at $1.17 and the price had moved by -22.52% over the past 365 days. In terms of relative price strength the Rockwell Medical share price has underperformed the S&P500 Index by -28.48% over the past year.
What are the analyst and broker recommendations for Rockwell Medical?
The overall consensus recommendation for Rockwell Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Rockwell Medical dividend yield?
Rockwell Medical does not currently pay a dividend.
Does Rockwell Medical pay a dividend?
Rockwell Medical does not currently pay a dividend.
When does Rockwell Medical next pay dividends?
Rockwell Medical does not currently pay a dividend.
How do I buy Rockwell Medical shares?
To buy shares in Rockwell Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rockwell Medical?
As of the previous close price of $1.17, shares in Rockwell Medical had a market capitalisation of $39.98m.
Where are Rockwell Medical shares listed?
Here are the trading details for Rockwell Medical:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RMTI
What kind of share is Rockwell Medical?
Based on an overall assessment of its quality, value and momentum Rockwell Medical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rockwell Medical share price forecast for 2025?
The analyst consensus target price for shares in Rockwell Medical is $4.00. That is 241.88% above the last closing price of $1.17.
Analysts covering Rockwell Medical currently have a consensus Earnings Per Share (EPS) forecast of -$0.17 for the next financial year.
Find out moreWhat is the trend in the Rockwell Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rockwell Medical. Over the past six months, its share price has underperformed the S&P500 Index by -67.12%.
As of the last closing price of $1.17, shares in Rockwell Medical were trading -50.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rockwell Medical PE Ratio?
The Rockwell Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.17.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rockwell Medical?
Rockwell Medical's management team is headed by:
- John McLaughlin - NEC
- Russell Ellison - PRE
- Russell Skibsted - CFO
- Paul McGarry - CAO
- Michael DeYoung - VOP
- Marc Hoffman - OTH
- Raymond Pratt - OTH
- John Cooper - IND
- Allen Nissenson - IND
- Robert Radie - IND
- Mark Ravich - IND
- Andrea Smiley - IND